A comprehensive review of oral glucosamine use and effects on glucose metabolism in normal and diabetic individuals

Simon, Ryan; Leeds, Anthony; Anderson, James W.

doi:10.1002/dmrr.1150

Cited by 80 publications

(70 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite some studies suggesting similar effects in 425 humans, systematic reviews of clinical studies have identified limited evidence for an 426 effect of oral glucosamine on insulin sensitivity or glucose tolerance in human subjects, 427 but acknowledge the need for further study in subjects with existing risk of impaired 428 glucose metabolism (Anderson et al 2005;Dostrovosky et al 2011;Simon et al 2011). 429…”

Section: Discussion 325mentioning

confidence: 99%

Altered pregnancy outcomes in mice following treatment with the hyperglycaemia mimetic, glucosamine, during the periconception period

Schelbach

Robker

Bennett

et al. 2013

Reprod. Fertil. Dev.

View full text Add to dashboard Cite

To protect the significant investment by both parties, CSIRO PUBLISHING requires an exclusive, worldwide Licence to Publish that clearly stipulates our rights and the specific rights retained by our authors. Authors retain the right to: […]  Place his/her pre-publication version of the work on a pre-print server  Place his/her pre-publication version of the work on a personal website or institutional repository on condition that there is a link to the definitive version on the CSIRO PUBLISHING web site. and further assessed the effects in overweight, high fat-fed mice. Eight week old mice 6 received daily glucosamine injections (20 or 400 mg/kg) for 3-6 days before and 1 day 7 after mating (periconception). Outcomes were assessed at day 18 gestation. 8Glucosamine treatment reduced litter size, independent of dose. A high fat diet (21% fat) 9 for 11 weeks prior to and during pregnancy reduced fetal size. No additional effects of 10 periconception glucosamine (20 mg/kg) on pregnancy outcomes were observed in fat-fed 11 mice. In mice fed control 6% fat diet glucosamine treatment at 16 weeks of age reduced 12 fetal weight and increased congenital malformations. As differing effects of glucosamine 13were observed in 8-week and 16-week old control mice, maternal age effects were 14 assessed. Periconception glucosamine at 8 weeks reduced litter size, while glucosamine 15 treatment at 16 weeks reduced fetal size. Thus, in vivo periconception glucosamine 16 exposure perturbs reproductive outcomes in mice, with the nature of the outcomes 17 dependent upon maternal age. 18 19

show abstract

Section: Discussion 325mentioning

confidence: 99%

Altered pregnancy outcomes in mice following treatment with the hyperglycaemia mimetic, glucosamine, during the periconception period

Schelbach

Robker

Bennett

et al. 2013

Reprod. Fertil. Dev.

View full text Add to dashboard Cite

show abstract

“…This position has been endorsed by recent reviews on the topic [38-40]. But we do not want to ignore the few studies hypothesizing that glucosamine may affect glucose metabolism, at least in subjects with untreated diabetes or glucose intolerance [41, 42].…”

Section: Discussionmentioning

confidence: 95%

Crystalline Glucosamine Sulfate in the Treatment of Osteoarthritis: Evidence of Long-Term Cardiovascular Safety from Clinical Trials

Reis

Giacovelli²,

Girolami³

et al. 2011

TORJ

View full text Add to dashboard Cite

Background and Objective:Glucosamine is a safe and common treatment for osteoarthritis. Even so, literature data on the cardiovascular safety of glucosamine are limited. The objective of this paper is to investigate the long-term effects of crystalline glucosamine sulfate (CGS) on key measures of cardiovascular risk in patients with osteoarthritis.Methods: We analyzed safety data from two long-term (6-month and 3-year, respectively) randomized controlled trials of CGS. Mean changes in blood pressure, lipids, and glucose were calculated for all patients randomized to CGS or placebo in either study and for subgroups with abnormally elevated baseline values. Shift tables were used to analyze transitions from normal to abnormal levels, or vice versa.Results:This analysis on 428 osteoarthritis patients includes data from subjects who had, on average, high normal blood pressure or high cholesterol at baseline. There were no significant changes in mean blood pressure after 6 months on CGS (systolic: -5±15 mmHg; diastolic: -5±10 mmHg) or placebo (systolic: -7±14 mmHg; diastolic: -4±10 mmHg). Subgroup analysis did not show significant effects in subjects with hypertension. Likewise, blood lipids (total/LDL cholesterol) and blood glucose did not change over 3 years and 6 months of treatment, respectively, even in hypercholesterolemic or hyperglycemic subjects. The proportions of patients whose blood pressure or cholesterol levels shifted from normal to abnormal, or vice versa, were comparable in the CGS and placebo groups.Conclusions:Long-term use of CGS did not affect blood pressure, lipids, or glucose in patients with osteoarthritis. These findings further support the cardiovascular safety of CGS.

show abstract

“…However, the role of one metabolite, glucosamine, in T2D in humans is unclear. Glucosamine infusion in nondiabetic rats decreases insulin-mediated glucose uptake and glycogen synthesis in skeletal muscle [34], but glucosamine has shown no effect on insulin-mediated metabolism in humans [35]. …”

Section: Discussionmentioning

confidence: 99%

Validation of a metabolite panel for early diagnosis of type 2 diabetes

et al. 2016

View full text Add to dashboard Cite

Background Accurate, early diagnosis of type 2 diabetes (T2D) would enable more effective clinical management and a reduction in T2D complications. Therefore, we sought to identify plasma metabolite and protein biomarkers that, in combination with glucose, can better predict future T2D compared with glucose alone. Methods In this case-control study, we used plasma samples from the Bavarian Red Cross Blood Transfusion Center study (61 T2D cases and 78 non-diabetic controls) for discovering T2D-associated metabolites, and plasma samples from the Personalized Medicine Research Project in Wisconsin (56 T2D cases and 445 non-diabetic controls) for validation. All samples were obtained before or at T2D diagnosis. We tested whether the T2D-associated metabolites could distinguish incident T2D cases from controls, as measured by the area under the receiver operating characteristic curve (AUC). Additionally, we tested six metabolic/pro-inflammatory proteins for their potential to augment the ability of the metabolites to distinguish cases from controls. Results A panel of 10 metabolites discriminated better between T2D cases and controls than glucose alone (AUCs: 0.90 vs 0.87; p = 2.08 × 10−5) in Bavarian samples, and associations between these metabolites and T2D were confirmed in Wisconsin samples. With use of either a Bayesian network classifier or ridge logistic regression, the metabolites, with or without the proteins, discriminated incident T2D cases from controls marginally better than glucose in the Wisconsin samples, although the difference in AUCs was not statistically significant. However, when the metabolites and proteins were added to two previously reported T2D prediction models, the AUCs were higher than those of each prediction model alone (AUCs: 0.92 vs 0.87; p = 3.96 × 10−2 and AUCs: 0.91 vs 0.71; p = 1.03 × 10−5, for each model, respectively). Conclusions Compared with glucose alone or with previously described T2D prediction models, a panel of plasma biomarkers showed promise for improved discrimination of incident T2D, but more investigation is needed to develop an early diagnostic marker.

show abstract

A comprehensive review of oral glucosamine use and effects on glucose metabolism in normal and diabetic individuals

Cited by 80 publications

References 56 publications

Altered pregnancy outcomes in mice following treatment with the hyperglycaemia mimetic, glucosamine, during the periconception period

Altered pregnancy outcomes in mice following treatment with the hyperglycaemia mimetic, glucosamine, during the periconception period

Crystalline Glucosamine Sulfate in the Treatment of Osteoarthritis: Evidence of Long-Term Cardiovascular Safety from Clinical Trials

Validation of a metabolite panel for early diagnosis of type 2 diabetes

Contact Info

Product

Resources

About